Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga/177Lu-PSMA theranostics in recurrent grade 3 and grade 4 glioma
2021-006810-35Phase 2Active
- Sponsor
- Norwegian University of Science and Technology
- Start
- May 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 PSMA I&T in glioma, sponsored by Norwegian University of Science and Technology. Started May 2022; status: active.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
glioma
Beyond the preview
Go deeper on 2021-006810-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006810-35.